Literature DB >> 10438058

The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins.

J M Heimlich1, F E Regnier, J L White, S L Hem.   

Abstract

Vaccines prepared by adsorbing an antigen onto an aluminium-containing adjuvant are usually administered by intramuscular or subcutaneous injection. The vaccine then comes in contact with interstitial fluid which contains proteins. In vitro displacement studies were performed to determine whether antigens, which are adsorbed to aluminium-containing adjuvants, can be displaced by interstitial proteins. It was found that when previously adsorbed model antigens such as lysozyme or myoglobin were exposed to interstitial proteins such as albumin or fibrinogen that extensive displacement occurred. A factorial study of the displacement of myoglobin from aluminium hydroxide adjuvant by albumin was performed. The displacement occurred rapidly with the majority of the displacement occurring in less than 15 min. Whether the concentration of the adsorbed myoglobin was above or below the adsorptive capacity of the aluminium hydroxide adjuvant affected the amount which could be displaced. Less myoglobin was displaced when the concentration was below the adsorptive capacity. The age of the model vaccine (1, 2 or 7 days) prior to exposure to the interstitial protein did not influence the amount of myoglobin that was displaced. The affinity of model antigens and interstitial proteins for aluminium hydroxide or aluminium phosphate adjuvant was characterized by the adsorption coefficient in the Langmuir equation. In every case studied, the protein having the larger adsorption coefficient was able to displace the protein with the smaller adsorption coefficient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438058     DOI: 10.1016/s0264-410x(99)00126-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  The role of adjuvant in mediating antigen structure and stability.

Authors:  Latoya Jones Braun; Aimee M Eldridge; Jessica Cummiskey; Kelly K Arthur; Deborah S Wuttke
Journal:  J Pharm Sci       Date:  2011-12-28       Impact factor: 3.534

4.  Concentration determination of a recombinant vaccine antigen adsorbed onto an alum adjuvant by chemiluminescent nitrogen detection.

Authors:  John V Amari; Philip Levesque; Zhirui Lian; Trish Lowden; Uditha deAlwis
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

5.  Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Authors:  Karen A Near; Anthony W Stowers; Dragana Jankovic; David C Kaslow
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.

Authors:  J S Lee; P Pushko; M D Parker; M T Dertzbaugh; L A Smith; J F Smith
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 7.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Authors:  Yuhong Xiao; Yuhong Zeng; Edward Alexander; Shyam Mehta; Sangeeta B Joshi; George W Buchman; David B Volkin; C Russell Middaugh; Stuart N Isaacs
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

Review 9.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

10.  Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.

Authors:  Daming Zhu; Shuhui Huang; Holly McClellan; Weili Dai; Najam R Syed; Elizabeth Gebregeorgis; Kelly M Rausch; Gregory E D Mullen; Carole Long; Laura B Martin; David Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.